Fludeoxyglucose (18f) Injection 0.5 Gbq (Fludeoxyglucose 18f SOLUTION) 0.5 GBQ

Fludeoxyglucose (18F) Injection 0.5 GBQ is a radiopharmaceutical solution used for diagnostic imaging. This intravenous injection is commonly associated with positron emission tomography (PET) scans to evaluate metabolic activity in the body.

Strength

0.5 GBQ

Manufacturer / TM Owner

BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fludeoxyglucose (18F) Injection is primarily used in positron emission tomography (PET) scans. These scans help in visualizing metabolic processes and identifying areas of high glucose metabolism, which can be useful in various diagnostic procedures. The injection is often utilized to assess conditions where understanding metabolic activity is crucial.

Side Effects

The effects of Fludeoxyglucose (18F) Injection are typically observed through imaging results. Patients may experience minimal discomfort at the injection site, but significant side effects are rare. The primary purpose of the injection is to provide clear images for diagnostic evaluation.

Precautions & Warnings

Handling Fludeoxyglucose (18F) Injection requires adherence to safety protocols due to its radioactive nature. It should be administered by trained healthcare professionals in a controlled environment. Patients should inform their healthcare provider about any allergies or medical conditions before receiving the injection.

Avoid Interactions

Fludeoxyglucose (18F) Injection may interact with certain medications or substances that affect glucose metabolism. It is important to discuss all current medications with a healthcare provider before undergoing a PET scan. Alcohol and other substances that alter metabolic processes could potentially interfere with the accuracy of the scan.

Frequently Asked Questions

Fludeoxyglucose (18F) Injection is used in positron emission tomography (PET) scans to visualize metabolic activity in the body.

The injection is administered intravenously by trained healthcare professionals in a controlled environment.

Common side effects are minimal, but patients may experience discomfort at the injection site.

Precautions include informing healthcare providers about allergies or medical conditions and following safety protocols due to its radioactive nature.

It may interact with medications that affect glucose metabolism, so discuss all current medications with a healthcare provider.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.